Dividend Aristocrat AbbVie (ABBV) will raise its quarterly dividend by another 10.2 percent to $1.30 per share in Q1 of 2021. Last year Abbvie announced a 10.3 percent dividend hike, marking 48 consecutive years of dividend increases.

The increased dividend is payable on February 16, 2021 to shareholders of record as of January 15, 2021. A new annual dividend rate of $5.20 per share yields 6.1% at a stock price of $85.10.

Since the company's inception in 2013, AbbVie has increased its quarterly dividend by 225 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

AbbVie Inc. is a research-based biopharmaceutical company. The company has business in therapeutic areas including, eye care, immunology, oncology, virology, women's health, gastroenterology and neuroscience. AbbVie’s products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. Abbvie's Humira medicine (for treatment of psoriasis and rheumatoid arthritis) is the world's best selling prescription medicine.  AbbVie became an independent company as a result of the distribution by Abbott Laboratories of 100% of the outstanding common stock of AbbVie to Abbott’s shareholders. In 2019 Abbvie completed the acquisition of Allergan PLC know for its Botox brand.